Cite

    Leus, A. et al. (2022). Eligibility criteria for programmed death receptor 1 inhibitors vs. real‐world advice: a retrospective analysis of 69 patients with advanced cutaneous squamous cell carcinoma of the head and neck. British journal of dermatology. pp. 371-372. [Online].